Cellectis plans 70% workforce cuts; Sanofi signs $1.2B DNA medicines deal; AstraZeneca buys Omniose
Cellectis plans to cut 70% of its workforce by 2027, focusing on gene-editing treatments. Sanofi partners with Seawolf for DNA-based medicines, potentially worth $1.2B. AstraZeneca acquires Omniose for bacterial vaccine tech. Nuformix proposes a merger with Biovara for respiratory drugs. Biomatter raises $18M for AI enzyme design.



